Pimavanserin
| Title | Journal |
|---|---|
| Pimavanserin for the treatment of Parkinson's disease psychosis. | Expert opinion on pharmacotherapy 20131001 |
| Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. | Schizophrenia research 20121101 |
| Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120901 |
| Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. | Behavioural pharmacology 20120801 |
| The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. | Psychopharmacology 20120501 |
| The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease. | Parkinson's disease 20120101 |
| Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. | The Journal of pharmacology and experimental therapeutics 20111001 |
| Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. | Behavioural pharmacology 20111001 |
| Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. | Psychopharmacology 20110901 |
| Serotonin 2A receptor antagonists for treatment of schizophrenia. | Expert opinion on investigational drugs 20110901 |
| The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. | The Journal of pharmacology and experimental therapeutics 20110801 |
| Newer molecules in the treatment of schizophrenia: A clinical update. | Indian journal of pharmacology 20110401 |
| Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain. | Journal of molecular neuroscience : MN 20110301 |
| Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. | Sleep medicine 20110201 |
| New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. | Parkinson's disease 20110101 |
| Inverse agonism and its therapeutic significance. | Indian journal of pharmacology 20110101 |
| Parkinson's disease dementia. | Current neurology and neuroscience reports 20100701 |
| Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100301 |
| Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects. | Drugs of today (Barcelona, Spain : 1998) 20100301 |
| Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. | The Journal of pharmacology and experimental therapeutics 20100201 |
| Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. | Expert opinion on pharmacotherapy 20081201 |
| A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. | Pharmacology, biochemistry, and behavior 20081001 |
| PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. | The international journal of neuropsychopharmacology 20080301 |
| Aripiprazole's receptor pharmacology and extrapyramidal side effects. | The American journal of psychiatry 20080301 |
| 5-HT(2A) inverse-agonists for the treatment of insomnia. | Current topics in medicinal chemistry 20080101 |
| ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. | The Journal of pharmacology and experimental therapeutics 20070801 |
| The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers. | Journal of clinical pharmacology 20070701 |
| Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. | Journal of clinical pharmacology 20070601 |
| ACP-103, a 5-HT2A receptor inverse agonist. | Current opinion in investigational drugs (London, England : 2000) 20060701 |
| Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. | The Journal of pharmacology and experimental therapeutics 20060501 |
| Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist. | The Journal of pharmacology and experimental therapeutics 20040901 |